Limiting research on molecular targeted therapies in advanced solid cancers: beyond a cost-effectiveness ratio analysis

Biomark Med. 2019 Aug;13(11):887-890. doi: 10.2217/bmm-2019-0216. Epub 2019 Jul 18.
No abstract available

Keywords: drug repurposing; financial resources; solid cancer; target therapy; therapeutic strategy.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Biomarkers / blood
  • Cost-Benefit Analysis
  • Drug Repositioning / economics
  • Humans
  • Molecular Targeted Therapy* / economics
  • Neoplasms / blood
  • Neoplasms / drug therapy*
  • Neoplasms / economics

Substances

  • Antineoplastic Agents
  • Biomarkers